The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.
ASJC Scopus subject areas
- Cancer Research